UGC
The global biosimilars market is driven by factors such as rising demand for biosimilars due to their cost-effectiveness and growing prevalence of chronic diseases.Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers to sustain their position in the market.For instance, in October 2018, Sandoz, a Novartis division received the US Food and Drug Administration (FDA) approval for its biosimilar, HyrimozTM (adalimumab-adaz) for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PSA),  juvenile idiopathic arthritis (JIA) in patients four years of age and older, ulcerative colitis (UC), ankylosing spondylitis (AS), adult Crohn's disease (CD), and plaque psoriasis (Ps)Biosimilars Market SegmentationGlobal Biosimilars Market has been segmented based on product, applications, end users, and region.The market, based on product, has been bifurcated into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides.The recombinant non-glycosylated proteins are further divided into human growth hormone (RHGH), granulocyte colony-stimulating factor (filgrastim), insulin, and interferons.Similarly, the recombinant glycosylated proteins segment is further bifurcated into erythropoietin (EPO), monoclonal antibodies (MABS), and follitropin.Thus, the therapeutic use of recombinant non-glycosylated proteins is broadening as their increased availability and lowered price.For example, according to the International Diabetes Federation (IDF), in 2017, approximately 425 million adults aged between 20 to 79 years suffered from diabetes, and this number is expected to rise to 629 million by 2045.On the basis of applications, the global biosimilars market has been divided into oncology, chronic diseases, autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others.Western Europe has further been classified as France, the UK, Germany, Italy, Spain, and the rest of Western Europe.
2
The same impurity that caused several blood pressure medication recalls last year is the source of another drug recall, this one involving a popular medication used to treat type-2 diabetes. The voluntary recall spans the entire United States and comes from Sun Pharmaceutical Industries, which found that some of its metformin hydrochloride extended-release medication (sold as RIOMET ER) may have … Continue reading
10
The US Food and Drug Administration has cautioned against misuse of over-the-counter drugs, after fears that the so-called “Benadryl Challenge” popular among some TikTok users could lead to injuries or even death. It’s the latest warning from the FDA in a year with more than its share of drug concerns, as unofficial uses for medications – both prescription and otherwise … Continue reading
6
Fast, high-tech, use-anywhere diagnostic tests are key to battling pandemics
6
"FDA relies on public trust and the FDA staff I have worked with and befriended in over a decade of practice understand this keenly," Marc Sanchez said.
6
Apple recently released the Apple Watch Series 6 and this time, it introduces an oximeter. The oximeter allows this smartwatch to measure the user’s blood ... The post Apple Watch Series 6 blood oxygen measurement is “mostly useless” appeared first on Gizchina.com.
6
App's creators hope that it could enable children with autism to be identified younger, thereby getting the help they need sooner.
7
Samsung is enabling ECG readings for its Galaxy Watch 3 and Galaxy Watch Active 2, upgrading the health-tracking feature having recently received FDA approval. The ability to take electrocardiogram readings puts the two smartwatches in relatively rare company, including the Apple Watch and a handful of others. Back when Samsung first unveiled the wearables, FDA approval was still in the … Continue reading
2
The startup Cognoa has submitted its app-based tool for FDA clearance
3
UGC
Market HighlightsBlood group typing is a type of test that is used to determine the blood group.The rising demand for blood and blood products, increasing prevalence of road accidents and trauma cases that make blood transfusion necessary, need for knowing the blood group for prenatal testing, and rising usage of blood group typing in forensic sciences are the factors driving the growth in this market.On the other hand, stringent government rules for blood transfusion, lack of skilled and trained blood transfusion professionals may hinder the growth of the market during the forecast period.Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6410  The global blood group typing market is currently dominated by many market players.The prominent players in the market are engaged in frequent new product launches and strategic collaborations to strengthen its market position.For instance, in October 2016, Bio-Rad laboratories got an approval from the US Food and Drug Administration (FDA) for its IH-1000 blood equipment.Regional AnalysisThe market in the Americas is expected to dominate the global blood group typing market during the forecast period owing to the growing prevalence of cancer and several diseases, increasing rate of organ transplant, and presence of well-developed healthcare sector.According to an article published by the National Foundation for Cancer Research in September 2017, blood cancers account for 10% of all cancer cases in the US.
Only days after the previous dog food recall, the FDA is drawing attention to another voluntary recall of dog food, this time over the risk of Salmonella contamination. The recall impacts one dog food brand and shouldn’t be mistaken for the dog food recall from earlier this month, which involved the presence of a potentially deadly toxin that results from … Continue reading
7
(Nanyang Technological University) Cancer cells are killed in lab experiments and tumour growth reduced in mice, using a new approach that turns a nanoparticle into a 'Trojan horse' that causes cancer cells to self-destruct, a research team at the Nanyang Technological University, Singapore (NTU Singapore) has found.
5
(Medical University of South Carolina) Of patients who seek treatment for alcohol use disorder, 60% to 80% relapse within a year. Taking the medication naltrexone reduces this number by a third. Yet only 20% of patients receive medications because they do not work well for everyone. Medical University of South Carolina researchers report in Alcoholism: Clinical and Experimental Research that measuring variants in just three brain genes makes it is possible to predict who will benefit from naltrexone.
3
In the time of COVID, pulse oximeters are the new thermometers, on the shelves of many medicine cabinets. But do they belong in wristwatches?
7
More

Top